Trial Profile
Improving the Selection of Patients With Glioblastoma Multiforme for Treatment With Epidermal Growth Factor Receptor Inhibitor Therapies.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Gefitinib (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 22 Jan 2018 Status changed from active, no longer recruiting to completed.
- 19 Jul 2016 Status changed from withdrawn prior to enrolment to active, no longer recruiting.
- 26 Jul 2013 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.